NeuroOne Medical Technologies (NASDAQ:NMTC) Price Target Raised to $8.00

Posted by George Bondi on May 16th, 2026

NeuroOne Medical Technologies (NASDAQ:NMTC – Free Report) had its price target lifted by LADENBURG THALM/SH SH from $1.60 to $8.00 in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

NMTC has been the subject of a number of other reports. Zacks Research cut shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 13th. Wall Street Zen upgraded shares of NeuroOne Medical Technologies to a “sell” rating in a research report on Saturday, February 21st. Weiss Ratings cut shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. Finally, JonesTrading began coverage on shares of NeuroOne Medical Technologies in a research report on Monday, March 2nd. They set a “buy” rating and a $9.00 price objective for the company. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $11.67.

Check Out Our Latest Stock Report on NeuroOne Medical Technologies

NeuroOne Medical Technologies Trading Down 8.5%

Shares of NASDAQ:NMTC opened at $4.21 on Wednesday. The firm has a 50 day moving average of $4.55 and a 200-day moving average of $4.55. The stock has a market capitalization of $36.29 million, a PE ratio of -4.95 and a beta of 0.60. NeuroOne Medical Technologies has a 12 month low of $3.27 and a 12 month high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The firm had revenue of $2.39 million during the quarter, compared to analyst estimates of $2.58 million. NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 98.33%. On average, research analysts predict that NeuroOne Medical Technologies will post -0.35 EPS for the current fiscal year.

Insider Transactions at NeuroOne Medical Technologies

In other NeuroOne Medical Technologies news, insider David J. Wambeke purchased 166,666 shares of the firm’s stock in a transaction on Sunday, March 1st. The stock was purchased at an average cost of $4.02 per share, for a total transaction of $669,997.32. Following the transaction, the insider owned 166,666 shares in the company, valued at $669,997.32. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 2,438 shares of company stock valued at $11,702. Corporate insiders own 11.80% of the company’s stock.

Hedge Funds Weigh In On NeuroOne Medical Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd increased its position in NeuroOne Medical Technologies by 321.1% in the 4th quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock valued at $65,000 after acquiring an additional 65,163 shares during the period. Squarepoint Ops LLC acquired a new position in NeuroOne Medical Technologies in the 4th quarter valued at approximately $36,000. Essex Investment Management Co. LLC acquired a new position in NeuroOne Medical Technologies in the 4th quarter valued at approximately $143,000. Renaissance Technologies LLC increased its position in NeuroOne Medical Technologies by 10.2% in the 4th quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock valued at $578,000 after acquiring an additional 70,428 shares during the period. Finally, Legato Capital Management LLC acquired a new position in NeuroOne Medical Technologies in the 4th quarter valued at approximately $34,000. 16.07% of the stock is currently owned by institutional investors and hedge funds.

About NeuroOne Medical Technologies

(Get Free Report)

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.